The Risk of Infection Human Papilloma Virus Infection in Acceptors of Depot Medroxyprogesterone Acetate Contraceptions

Objective: Cervical cancer is the second most prevalent cancer in women around the world and the most common cancer in women causing death. This study aims to analyze the connection between infection of human papilloma virus (HPV) 16/18 and cervical changes in the acceptors of Depot Medroxyprogesterone Acetate (DMPA) Contraceptions and nonacceptors of Depot Medroxyprogesterone Acetate (DMPA) Contraceptions. Methods: The research was conducted at the Public Service Institution of Dr. Wahidin Sudirohusodo hospital, and private midwife clinics for seven months from December 2015 to June 2016. The research design is cross-sectional with. The samples were forty acceptors of Depot Medroxyprogesterone Acetate (DMPA) and forty non-acceptors of Depot Medroxyprogesterone Acetate (DMPA) contraception. Prevalence of HPV 16/18 and cervical cytology changes were examine using the polymerase chain reaction and liquid base cervical cytology. Results: The results showed there was no significant relationship between long-term use of DMPA contraceptives with HPV 16 and 18. There was no significant relationship between long-term use of DMPA contraceptives with cervical cytology changes. There was no significant relationship between HPV 16 and 18 infections with the occurrence of cervical cytology changes in long-term use of DMPA contraceptives. Conclusion: The long-term use of DMPA contraceptive does not increase the risk of HPV 16 and 18 infections. Also does not cause cervical cytology changes that lead to cervical malignancy. Keywords: cervical cytology changes, Depot Medroxyprogesterone Acetate (DMPA) contraception, HPV 16/18 infection

Abstract licence: CC BY-NC-SA

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.